Clinical update on TP-05 puts Tarsus Pharmaceuticals (TARS) in focus

Tarsus Pharmaceuticals (TARS) recently updated investors on its ongoing Phase 2b trial of TP-05, an oral tablet being tested to help prevent Lyme disease in high risk individuals.

The recent TP-05 update comes as Tarsus trades at US$63.48, with the share price down 21.41% year to date but a 1 year total shareholder return of 47.73% and a very large 3 year total shareholder return that hints at momentum built over a longer period.

If TP-05 has sparked your interest in healthcare and disease prevention, it could be a good time to broaden your research with other potential opportunities in 33 healthcare AI stocks

With Tarsus trading at US$63.48, showing a 47.73% 1 year total return but down 21.41% year to date, and sitting well below some analyst targets, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 33.3% Undervalued

With Tarsus closing at $63.48 against a narrative fair value of $95.11, the current price sits well below what this widely followed framework suggests.

Accelerated patient and physician adoption of XDEMVY, driven by a robust direct to consumer campaign and increased unaided awareness, points to ongoing demand expansion among an estimated 25 million potential U.S. patients, suggesting material runway for future top line revenue growth.

Curious what kind of revenue path and margin shift would need to play out to support that higher fair value, and how long that runway really looks? The story here hinges on how quickly a relatively new product category scales, how efficiently those extra dollars could convert into profit, and what sort of earnings multiple the market might accept if it all lines up. If you want to see the full set of assumptions that tie those moving parts together, the complete narrative lays it out in detail.

Result: Fair Value of $95.11 (UNDERVALUED)

However, this upbeat story still leans heavily on XDEMVY continuing to gain traction. High ongoing SG&A spend and a relatively concentrated product base could pressure profitability if uptake slows.

Next Steps

With mixed sentiment across risks and rewards, this is a moment to move quickly, review the data for yourself, and weigh the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with just one stock, you risk missing other clear opportunities. Keep your options open and let data driven ideas work for you.

• Spot potential bargains early by scanning a focused list of screener containing 20 high quality undiscovered gems that pair solid fundamentals with limited market attention.
• Prioritize capital preservation by reviewing 66 resilient stocks with low risk scores that show resilient metrics and lower overall risk scores.
• Hunt for quality and value together by using the solid balance sheet and fundamentals stocks screener (46 results) to surface companies with stronger financial footing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.